Published ·
Vitamins from China: supply-chain risk starts before the finished product
Concentrated production stages are only half the story. Pharmaceutical starting materials also require defined storage conditions, status control and traceability — the interface where Inter-Pharma combines expertise with operations.
Concentration is a risk — not one universal percentage
Important industrial stages for various vitamins and intermediates are located in China. The degree of dependency varies by vitamin, grade, synthesis stage and intended use, so a single market percentage would be misleading. The operational test is whether qualified alternatives, upstream visibility and sufficient reaction time exist.
The critical interface sits between sourcing and use
A second supplier alone does not create resilience. Specification, audit and approval status, transport conditions, replenishment time, batch documents and practical storage capability must align. Material that is available but arrives under unsuitable conditions or without an unambiguous quality status is not reliable supply.
Starting materials follow distinct, strict frameworks
Finished human medicines are covered by the EU GDP guidelines. Active substances for human medicines have their own GDP guideline, while EudraLex Volume 4 Part II sets GMP principles for active substances used as starting materials. Excipients and food, feed or cosmetic grades follow other applicable systems. Intended use — not the generic word ‘vitamin’ — determines the framework.
What a robust warehouse process must control
Before receipt, the material, manufacturer, supplier, origin, batch, specification, packaging, temperature, humidity, light protection and contamination risks must be defined. Warehouse control includes quarantine, released and rejected status, segregated locations, documented monitoring, access and hygiene rules, FIFO or FEFO, and traceable handover to sampling, quality control or production.
Inter-Pharma: expertise translated into operations
Inter-Pharma connects supply-chain analysis with warehouse operations in Cheb. We assess pharmaceutical starting materials, APIs, excipients and packaging separately from finished medicines and translate specifications into receipt, status, storage, monitoring and escalation processes. Explore our pharmaceutical raw-material, API and packaging warehousing. This interface between sourcing, quality and physical operations is where our knowledge becomes business value.
Frequently asked questions
Does GDP automatically apply to every vitamin?
No. The applicable framework depends on product status, intended use and role. Finished medicines, active substances, excipients and food or cosmetic grades require separate assessment.
Is dual sourcing enough?
No. Alternative sources must be qualified, specification-compliant, documented, transportable and capable of being stored under the required conditions.